How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Scott Centea, insider at AngioDynamics

Scott Centea Insider Information

Scott entered AngioDynamics in 2005 as a sales representative serving the Carolinas.  He served in a variety of positions, culminating in his most recent promotion to Sr. Vice President/General Manager of Vascular Interventions and Therapies and Peripheral Artery Disease.

How old is Scott Centea?

Mr. Centea is currently 44 years old. There are 9 older executives and no younger executives at AngioDynamics. The oldest executive at AngioDynamics is Mr. James C. Clemmer, CEO, Pres & Director, who is 58 years old. Learn More on Scott Centea's age.

What is Scott Centea's salary?

As the VP of AngioDynamics, Inc., Mr. Centea earned a total compensation package of $841,368.00 in 2020. Mr. Centea earned a salary of $261,747.00, stock awards of $239,009.00, options awards of $230,710.00, non-equity compensation of $84,943.00, and other compensation of $24,959.00. Learn More on Scott Centea's salary.

How do I contact Scott Centea?

The corporate mailing address for Mr. Centea and other AngioDynamics executives is 14 PLAZA DRIVE, LATHAM NY, 12110. AngioDynamics can also be reached via phone at (518) 795-1400 and via email at [email protected] Learn More on Scott Centea's contact information.

Has Scott Centea been buying or selling shares of AngioDynamics?

Scott Centea has not been actively trading shares of AngioDynamics during the last ninety days. As far as recent transactions, 0 shares of the stock in a transaction dated Sunday, May 22nd. Learn More on Scott Centea's trading history.

Who are AngioDynamics' active insiders?

AngioDynamics' insider roster includes Chad Campbell (SVP), Scott Centea (VP), James Clemmer (CEO), James Clemmer (CEO), Dave Helsel (SVP), and Stephen Trowbridge (CFO). Learn More on AngioDynamics' active insiders.

Are insiders buying or selling shares of AngioDynamics?

During the last twelve months, AngioDynamics insiders bought shares 2 times. They purchased a total of 11,000 shares worth more than $251,040.00. During the last twelve months, insiders at the medical instruments supplier sold shares 5 times. They sold a total of 35,956 shares worth more than $946,030.10. The most recent insider tranaction occured on April, 28th when SVP Dave Helsel sold 3,513 shares worth more than $78,831.72. Insiders at AngioDynamics own 4.8 % of the company. Learn More about insider trades at AngioDynamics.

Information on this page was last updated on 4/28/2022.

Scott Centea Insider Trading History at AngioDynamics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/15/2021Sell12,000$27.92$335,040.00View SEC Filing Icon  
See Full Table

Scott Centea Buying and Selling Activity at AngioDynamics

This chart shows Scott Centea's buying and selling at AngioDynamics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AngioDynamics Company Overview

AngioDynamics logo
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $19.25
Low: $19.08
High: $19.61

50 Day Range

MA: $21.74
Low: $17.98
High: $24.49

2 Week Range

Now: $19.25
Low: $17.56
High: $32.00

Volume

300,543 shs

Average Volume

212,189 shs

Market Capitalization

$745.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.